left corner

right corner


Go to our worldwide corporate directory on www.actavis.com


Press Releases

27 MAR 2012 / Product News

Actavis launch Quetiapine on day-one to bring 2012 new product launches to fourteen

Actavis is proud to introduce Quetiapine film-coated tablets on day one following patent expiry. Quetiapine marks Actavis' seventh day-one patent expiry launch of the year to date.

From January 2012, Actavis has brought fourteen new products to market, including seven day-one patent expiries; Latanoprost, Latanoprost/Timolol, Donepezil, Donepezil ODT, Zolmitriptan, Zolmitriptan ODT, Quetiapine and seven additional new product lines.

Michael Cann, Director Generics said: "Actavis is delighted to have brought fourteen new products to market in the first three months of 2012, seven of which have been available to pharmacist on day-one of patent expiry.

"We work hard to deliver products on day-one and our launches over the first few months of 2012 reflects this. Our current portfolio is in excess of 585 prescription only products." 


Quetiapine is indicated for the treatment of schizophrenia and bipolar disorder. Other antipsychotic products in the Actavis portfolio include Risperidone and Olanzapine, which was launched on day-one in late September 2011.


Actavis is offering Quetiapine in packs of 60 film-coated tablets in 25mg, 100mg, 150mg, 200mg and 300mg strengths.


All products are available through major wholesalers or directly from the Actavis Customer Service team on telephone: 0800 731 0370 or fax: 0800 731 0380.

  • GoBack
  • Print
  • Send